Compugen Ltd News Today

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a buy rating in a research report report published on Tuesday. Separately, Truist Financial cut their price target on Compugen from $5.00 to $4.00 and set a buy rating for the company in a research note on Tuesday. View Our Latest […]

Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugens First Quarter 2024 Results Conference Call. At this time, all participants are in a listen-only mode.

Has released an update. Compugen Ltd., a clinical-stage immunotherapy company, has provided updates for Q1 2024, announcing complet...

Compugen Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 2.56 million. Net loss was USD 7.27 million compared to...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF...

Part of the reason for the CFO shakeup is more finance chiefs ascending to the top spot.

FOR IMMEDIATE RELEASE: Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in ...

PharmaCyte Biotech (OTCMKTS:PMCBD – Get Free Report) and Compugen (NASDAQ:CGEN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation. Profitability This table compares PharmaCyte Biotech and Compugen’s […]

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

FOR IMMEDIATE RELEASE: Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy ...